
Washington, DC—Topical mitomycin-C (MMC) (Mutamycin, Bristol-Myers Oncology) is an effective treatment for conjunctival primary acquired melanosis (PAM) with atypia, and may even be considered a superior alternative to surgical excision and cryotherapy, said Joseph Frucht-Pery, MD, at World Cornea Congress V.